Radich et al. did not find a statistically significant difference in CR or in survival in patients with NRAS-mutated AML compared to the unmutated group, and Bowen et al. did not find RAS mutations to affect OS, DFS, CR, or rate of relapse [185,186], In a study of 2502 patients with AML, 10.3% of patients had N-RAS mutations. The gene discussed is NRAS; the disease is acute myeloid leukemia.